List of Figures:
Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Million US$), 2014 & 2018
Figure 4-2: Global - ADCETRIS Market (Million US$), 2011-2013
Figure 4-3: Global - ADCETRIS Market (Million US$), 2014 & 2018
Figure 4-4: Global - Kadcyla Market (Million US$), 2014 & 2018
Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
Figure 5-2: Pipeline ADCs by Indication (2014)
Figure 5-3: Pipeline ADCs by Drug (2014)
List of Tables:
Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 6-1: ADCs in Pipeline
Table 7-1: Strategic Collaborations in the ADC Industry
Table 9-1: Seattle Genetics - ADCs in Pipeline
Table 9-2: Seattle Genetics - ADC Collaborator Pipeline
Table 9-3: Seattle Genetics - Strengths and Weaknesses
Table 9-4: Roche - ADC Collaborator Pipeline
Table 9-5: Roche - Strengths and Weaknesses
Table 9-6: Immunogen, Inc. - ADCs in Pipeline
Table 9-7: Immunogen, Inc. - ADC Collaborator Pipeline
Table 9-8: Immunogen, Inc. - Strengths and Weaknesses
Table 9-9: Immunomedics - ADCs in Pipeline
Table 9-10: Immunomedics - Strengths and Weaknesses
Table 9-11: Agensys, Inc. - ADC Collaborator Pipeline
Table 9-12: Agensys, Inc. - Strengths and Weaknesses